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Insulin resistance, tissue inflammation, and adipose
tissue dysfunction are features of obesity and
Type 2 diabetes. We generated adipocyte-specific
Nuclear Receptor Corepressor (NCoR) knockout
(AKO) mice to investigate the function of NCoR in
adipocyte biology, glucose and insulin homeostasis.
Despite increased obesity, glucose tolerance was
improved in AKO mice, and clamp studies demon-
strated enhanced insulin sensitivity in liver, muscle,
and fat. Adipose tissue macrophage infiltration and
inflammation were also decreased. PPARg response
genes were upregulated in adipose tissue from
AKO mice and CDK5-mediated PPARg ser-273
phosphorylation was reduced, creating a constitu-
tively active PPARg state. This identifies NCoR as
an adaptor protein that enhances the ability of
CDK5 to associate with and phosphorylate PPARg.
The dominant function of adipocyte NCoR is to
transrepress PPARg and promote PPARg ser-273
phosphorylation, such that NCoR deletion leads to
adipogenesis, reduced inflammation, and enhanced
systemic insulin sensitivity, phenocopying the TZD-
treated state.
INTRODUCTION
The adipocyte uses well regulated transcriptional programs to
adapt to environmental inputs through storage of calories as
triglycerides and secretion of adipokines and other factors
(Rosen and Spiegelman, 2006). PPARg is a key factor controlling
the importance of adipose tissue in whole-body glucose metab-
olism (Evans et al., 2004; Lehrke and Lazar, 2005; Saltiel and
Olefsky, 1996; Sugii et al., 2009; Tontonoz and Spiegelman,
2008). PPARg is a member of the nuclear hormone receptor
(NR) family and is highly enriched in adipose tissue, where itplays a critical role in adipocyte differentiation, insulin sensitivity,
and adipokine/cytokine secretion (Evans et al., 2004; Imai et al.,
2004; Rangwala and Lazar, 2004; Tontonoz and Spiegelman,
2008). Although its endogenous ligand is poorly understood,
PPARg is the molecular target for the thiazolidinedione (TZD)
class of insulin-sensitizing drugs used to treat type 2 diabetes.
Transcriptional control by NRs, including PPARg and others,
depends on multiprotein coregulatory complexes (Feige and
Auwerx, 2007; Fowler and Alarid, 2004; Hermanson et al.,
2002). In general, corepressor complexes are recruited to NRs
in the absence of ligand, whereas coactivator complexes are
recruited to NRs in the presence of agonists (Lonard and
O’Malley, 2005). Coactivators and corepressors modulate
gene transcription by a variety of mechanisms including histone
acetylation, chromatin remodeling, and direct interactions with
basal transcription complexes (Collingwood et al., 1999). There
are several coactivators, such as CBP, PGC1a, and CRTC2,
that are known to play important roles in metabolic control
(Handschin and Spiegelman, 2008; Revilla and Granja, 2009;
Wang et al., 2010). However, the role and underlying mecha-
nisms of corepressor function in metabolic tissues remains
unclear. Two major NR corepressors are the silencing mediator
of retinoid and thyroid hormone receptors (SMRT) and the
nuclear receptor corepressor (NCoR) (Chen and Evans, 1995;
Horlein et al., 1995). It has been shown that downregulation of
SMRT and NCoR expression in 3T3-L1 cells leads to enhanced
adipocyte differentiation, in part through increased PPARg
transcriptional activity (Yu et al., 2005). However, their role in adi-
pogenesis, adipocyte function, and glucose metabolism in vivo
remains uncertain. Since whole body NCoR deletion is embroni-
cally lethal (Jepsen et al., 2000), we generated adipocyte-
specific NCoR knockout (AKO) mice to assess the role of this
corepressor in glucose metabolism, insulin sensitivity, and adi-
pogenesis. We show that AKOmice develop increased adiposity
on HFD relative to WT controls. Despite this increase in obesity,
the AKO animals exhibit enhanced systemic insulin sensitivity,
improved glucose tolerance, and decreased adipose tissue
inflammation. Taken together, these features phenocopy the
effects of systemic TZD treatment.Cell 147, 815–826, November 11, 2011 ª2011 Elsevier Inc. 815
Figure 1. NCoR Targeting Strategy and Adipocyte-
Specific Deletion
(A) Shown (top to bottom) are wild-type, floxed, and
deleted NCoR gene loci. Primers used to distinguish WT
and floxed alleles and sizes of the expected PCR products
are indicated.
(B) Genotyping results of wild-type +/+, f/+, and f/f mice.
(C) Relative messenger RNA levels of NCoR in adipose
tissue and macrophages.
(D and E) Relative NCoR (D) and SMRT (E) mRNA levels in
various tissues.
Values are fold induction of gene expression normalized to
the housekeeping gene Gapdh and expressed as mean ±
SEM, n = 8–10 in (C)–(E), *p < 0.05, **p < 0.01 for AKO
versus WT. See also Table S1.RESULTS
NCoR Deletion in Adipocytes
To investigate the specific role of adipocyte NCoR on adipogen-
esis and on the development of insulin resistance in response to
HFD feeding, we generated adipocyte-specific knockout mice
(AKO) using the Cre-lox system (NCoRfl/fl; aP2-Cre+/–) (Figures
1A and 1B). As controls, floxed NCoR mice that do not express
Cre recombinase (Cre) were used (NCoRfl/fl; ap2-Cre/),
referred to, hereafter, as WT. As expected, NCoR expression
was greatly diminished in the epididymal adipose tissue of AKO
mice (Figure 1C). However, since aP2/Fabp4 can also be ex-
pressed inmacrophages,wedeterminedwhether aP2Cre-medi-
ated deletion of NCoR could be detected in this cell type. There
was no decrease in NCoR expression in intraperitoneal (IP)-
macrophages from the AKO mice (Figure 1C), consistent with
previous studies using this ap2-cre mouse line, showing adipo-
cyte restricted expression(He et al., 2003; Qi et al., 2009; Sabio
et al., 2008; Sugii et al., 2009). This explains the70% decrease
in NCoR expression in whole epididymal adipose tissue, since
NCoR is not deleted in macrophages or other nonadipocyte cell
types present in this tissue. Interestingly, the magnitude of
NCoR depletion in subcutaneous WAT and BAT was closer to
90%,most likely reflecting a lower amount of nonadipocytic cells,
such as immune cells, in these depots. As also shown in Fig-
ure 1D, therewas noNCoRdeletion in any other tissue examined.
SMRT is another corepressor, which in some contexts can func-
tion similarly to NCoR, but there were no changes in SMRT
expression in the AKO mice in any tissues (Figure 1E).
AKO Mice Are More Obese Than WT after HFD Feeding
To investigate the functional significance of adipocyte-specific
NCoR deletion, both WT and AKO mice were fed a 60% high-816 Cell 147, 815–826, November 11, 2011 ª2011 Elsevier Inc.fat diet (HFD) for up to 17 weeks, starting at
8 weeks of age. As expected, WT mice became
obese, but the AKOmice were evenmore obese
as shown in Figure 2A. Thus, the body weight of
the AKO mice was 15% greater than WT (Fig-
ure 2B) and this was accompanied by a 10%
increase in food intake (Figure 2C). To further
assess body composition changes accompa-
nying this increase in obesity, MRI analyseswere performed. As shown in Figures 2D–2F, the AKO mice ex-
hibited an increased volume of both subcutaneous and visceral
fat. Accordingly, epididymal fat mass doubled in AKO mice
compared to WT (Figure 2G), while there was no difference in
lean body mass (data not shown). Given that PPARg plays
a central role in the promotion of adipogenesis, these results
suggest constitutive activation of adipose tissue PPARg. Con-
sistent with this interpretation, Figure 2H shows increased
expression of the adipogenic PPARg response genes FAS,
ACC, SREBP1c, SCD1, and SCD2 in AKO adipose tissue
(Djaouti et al., 2010; Lessard et al., 2007; Paton and Ntambi,
2009; Sugii et al., 2009).
Deletion of NCoR in Adipose Tissue Protects against
HFD-Induced Systemic Insulin Resistance
Obesity leads to glucose intolerance aswell as insulin-resistance
in adipose tissue, liver, and muscle. Therefore, we assessed
glucose homeostasis and insulin sensitivity in lean chow-fed
and HFD-fed WT and AKO mice. No changes in glucose or
insulin tolerance, BW, fat-pad weight, or fasting insulin level,
were noted in the lean chow-fed mice between genotypes (Fig-
ure S1 available online). In contrast, in the context of HFD/
obesity, marked phenotypic changes in glucose and insulin
homeostasis emerged in the AKO mice. Basal insulin level was
reduced (Figures 3A and 3B), and upon glucose and insulin toler-
ance test, the AKO mice showed an enhanced hypoglycemic
response to the injected insulin (Figure 3C), as well as improved
glucose tolerance compared to controls (Figure 3D). In aggre-
gate, these results argue strongly for improved systemic insulin
sensitivity as a result of adipocyte NCoR deletion.
Tomore accurately quantify in vivo insulin action and to assess
tissue-specific sites of insulin sensitivity, hyperinsulinemic/
euglycemic clamp studies were performed. The amount of
Figure 2. Obese Phenotype of Adipocyte-Specific
NCoR Knockout Mice
(A) Photograph.
(B) Body weight.
(C) Food intake.
(D) Coronal section views of 3D MRI scan.
(E) Subcutaneous fat mass.
(F) Visceral fat mass.
(G) Epi-WAT weight.
(H) Adipogenic gene expression levels in Epi-WAT.
Values are expressed as mean ± SEM, n = 8–10 in (B), (C),
(E)–(H), *p < 0.05, **p < 0.01 for AKO versus WT. See also
Table S1 and Figure S1.exogenous glucose required to maintain euglycemia (GIR) and
the glucose disposal rate (GDR) during the clamp studies was
substantially higher in the AKO mice compared to WT (Figures
3E and 3F). The insulin-stimulated glucose disposal rate (IS-
GDR), which primarily reflects skeletal muscle insulin sensitivity
and insulin’s ability to suppress hepatic glucose production
(HGP), which reflects hepatic insulin sensitivity, was also
improved in the AKO group (Figures 3G–3I). Finally, the ability
of insulin to suppress plasma FFA levels provides an indication
of adipose tissue insulin sensitivity, and FFA suppression was
nearly twice as great in the AKO mice compared to WT (Fig-
ure 3J). We also harvested fat, liver, and muscle tissue for
ex vivo measurements of insulin action. As seen in Figures 3K–
3M, insulin-stimulated Akt phosphorylation was augmented in
all three tissues in the AKO mice compared to WT. Livers of
the obese AKO mice were markedly less steatotic compared
to WT by HE staining, with reduced expression of the lipogenic
genes, SREBP1c, FAS, and ACC (Figure S2). Similarly, in
muscle, we found a marked decrease in TAGs, DAGs, and ce-
ramides in the AKO group (Figure S2). Taken together, these
data demonstrate that deletion of NCoR from adipocytes leads
to a marked improvement in systemic insulin sensitivity, and
these effects were expressed in all three major insulin target
tissues, muscle, liver, and adipose tissue.
Adipocyte Function in WT and AKO Mice
Obesity represents an enlargement of adipose tissue to store
excess energy, and this is mostly accomplished by hypertrophy
of fat cells, with hyperplasia generally assuming a smaller role. In
chow-fed animals, the average epididymal adipocyte diameter
was 60 mm, and in age-matched HFD/obese mice, fat-cell diam-Cell 147, 815–eter increased dramatically to 219 mm in WT
mice. Interestingly, in the AKO group, the
increase in adipocyte size was less on HFD
(169 mM) (Figure 4A). This equates to a 54%
decrease in average adipocyte volume in the
AKO mice and per gm of adipose tissue there
are 19.8 3 104 fat cells in WT compared to 43 3
104 cells in the AKO animals. This indicates
that hyperplasia plays a greater role in adipose
tissue expansion in AKOmice, where adipocyte
PPARg is constitutively activated, and this
increase in fat-cell number accounts for thegreater adiposity in the AKO group. Interestingly, adipose tissue
PPARg levels (Figure 4B) were increased in the HFD AKO mice,
providing an additional potential mechanism for enhanced
PPARg signaling. In the lean chow-fed mice, no changes in
PPARg gene expression were noted in any of the adipose tissue
depots examined (Figure S3). We measured tissue cathepsin D
activity, perilipin content, and tunnel staining and found that
levels of cathepsin D and perilipin were lower in the AKO mice,
as was tunnel staining, indicative of lower rates of apoptosis/
necrosis (Figures 4C–4E). Brown adipose tissue (BAT) mass
and BAT-related gene expression were unchanged in the AKO
mice (Figure S4).
Besides storing lipids, adipose tissue functions as an endo-
crine organ, secreting a large number of polypeptide hormones,
termed adipokines, which can modify systemic glucose homeo-
stasis and insulin sensitivity. We measured adipokine levels in
the AKO mice and found lower levels of leptin, resistin, PAI-1,
but higher levels of HMW-adiponectin (Figure 4F), indicating
that deletion of NCoR in adipocytes led to an adipokine profile
favoring insulin sensitivity.
In adipose tissue, insulin promotes the uptake and storage of
fatty acids in the form of triglycerides and inhibits lipolysis of
stored triglycerides. Circulating levels of free fatty acids (FFA)
were lower in the AKO mice (Figure 4G), suggesting lower
rates of lipolysis in the adipose tissue. We also measured
insulin-stimulated glucose uptake in primary adipocytes and as
seen in Figure 4H, the ability of insulin to enhance glucose trans-
port was 30% higher in AKO versusWT adipocytes. This directly
demonstrates cell autonomous insulin sensitivity in AKO cells,
consistent with the insulin signaling data provided in Figure 3M.
Conditioned media (CM) harvested from LPS treated RAW264.7826, November 11, 2011 ª2011 Elsevier Inc. 817
Figure 3. Improved Glucose Metabolism and
Insulin Sensitivity in AKO Mice
(A) Fasting blood glucose levels.
(B) Fasting blood insulin levels.
(C) Insulin tolerance tests.
(D) Glucose tolerance tests.
(E) Glucose infusion rate (GIR) during hyperinsulinmic
euglycemic clamp.
(F) Glucose disposal rate (GDR).
(G) Insulin-stimulated glucose disposal rate (IS-GDR).
(H) Basal hepatic glucose production (HGP).
(I)PercentsuppressionofHGPby insulin (HGPsuppression).
(J) Percent suppression of free fatty-acid levels (FFA
suppression).
(K) Insulin-stimulated phospho-Akt (Ser473) in liver.
(L) Insulin-stimulated phospho-Akt (Ser473) in muscle.
(M) Insulin-stimulated phospho-Akt (Ser473) in adipose
tissue.
Values are expressed as mean ± SEM, n = 8–10 in (A)–(D),
n = 6 in (E)–(J), *p < 0.05, **p < 0.01 for AKO versus WT.
See also Figure S1 and Figure S2.macrophages contains high levels of secreted cytokines which
can inhibit insulin-stimulated glucose transport. Interestingly,
when adipocytes were treated with RAW 264.7 cell CM, the ex-
pected inhibition of glucose transport was observed in WT
adipocytes, but this effect of CMwas attenuated in the AKO cells
(Figure S3).
Macrophage Infiltration and Inflammation
in Adipose Tissue
Large numbers of adipose tissue macrophages (ATMs) accumu-
late in obesity and substantial evidence exists pointing to an
etiologic role for these cells in the development of chronic tissue
inflammation and insulin resistance/diabetes (Li et al., 2010;
Lumeng et al., 2007; Nguyen et al., 2007; Weisberg et al.,
2003; Xu et al., 2003). Thus, SVCs of epi-WAT depots from the
two groups were isolated and stained with F4/80 and CD11b
antibodies. This immunohistochemical analyses showed a large
increase in F4/80 and CD11b double-positive macrophages in
the WT mice after 17 weeks of HFD while ATM accumulation
was much less in the AKO group (Figure 5A). Consistent with
this, adipose tissue F4/80 mRNA expression was lower in the
AKO mice (Figure 5B). ATMs often surround dead adipocytes
to form crown-like structures (CLS) and there were fewer CLS
in the AKO mice compared to WT mice (Figure 5C). These find-
ings demonstrate that ATM content is diminished in the AKO
animals, despite the fact that they are more obese.
ATMs are heterogeneous, and there are at least two subpop-
ulations of F4/80+, CD11b+ ATMs—one of which is positive
and the other negative for CD11c. The CD11c+ (triply positive,818 Cell 147, 815–826, November 11, 2011 ª2011 Elsevier Inc.F4/80+, CD11b+, CD11c+ cells), M1-like, macro-
phages account for the majority of the increase
in ATMs in obesity and overexpress proinflam-
matory cytokines compared with the CD11c,
M2-like, ATMs (Hevener et al., 2007; Li et al.,
2010; Lumeng et al., 2007; Nguyen et al.,
2007). As shown in Figures 5D and 5E, there
was a marked decrease in CD11c+ ATMs inthe AKO mice compared to WT. Most proinflammatory genes,
including TNFa, IFNg, IL-1b, iNOS, IL12p40, COX2, and
MCP-1, were reduced in the AKOmice (Figure 5F), while expres-
sion of the noninflammatory M2 marker genes, arginase and
Mgl2, was increased. To expand this analysis, we measured
these mRNAs in adipocytes compared to SVCs (Figure S5).
These results were quite consistent with the whole adipose
tissue data in that proinflammatory gene expression was gener-
ally decreased in both the SVCs and adipocytes from AKOmice.
To assess the mechanisms underlying the decreased ATM
content in AKO mice, we measured the effects of CM from WT
and AKO primary adipocytes to induced macrophage chemo-
taxis. AKO CM-mediated in vitro chemotaxis was markedly
decreased compared to WT CM (Figure 5G), fully consistent
with the reduced ATM content in AKO adipose tissue. We
studied this concept further by directly measuring macrophage
migration into adipose tissue using an in vivo macrophage
tracking technique. With this approach, circulating monocytes
were obtained from aWT donor mouse and labeled with fluores-
cent PKH26 dye ex vivo. The labeled monocytes were then
injected into recipient HFD WT or HFD AKO mice. As seen in
Figure 5H, there was a substantial decrease in labeled macro-
phage appearance in adipose tissue in the AKO mice. These
data were even more revealing when we examined the sub-
populations of labeled macrophages between the genotypes.
With this analysis, (Figure 5I) there is an even greater decrease
in the number of recruited macrophages which express
CD11c, while at the same time there is an increase in the
CD11c macrophage population in the AKO mice.
Figure 4. Increased Adipogenesis and Reduced
Adipocyte Cell Death in AKO Mice
(A) Adipose tissue was stained for caveolin and adipocyte
diameter was quantified. (B) Relative mRNA levels of
PPARg, (C) Cathepsin D activity, (D) Perilipin staining, (E)
Tunnel staining, and (F) Circulating adipokine (leptin, high
molecular weight adiponectin, resistin and PAI-1) levels in
control and AKO mice. (G) Blood free-fatty-acid (FFA)
levels. (H) Basal and insulin-stimulated 2-DOG glucose
uptake in primary adipocytes. Values are expressed as
mean ± SEM, n = 8–10 in B, C, F and G. n = 5 in H, *p <
0.05, **p < 0.01 for AKO versus WT. See also Table S1 and
Figure S3.AKO Mice Are Relatively Refractory to PPARg
Stimulation
TZD treatment leads to increased insulin sensitivity, and we
assessed this by treating HFD WT and HFD AKO mice with the
PPARgagonist Rosiglitazone for 3weeks, followedby hyperinsu-
linemic-euglycemic clamp studies. The data in Figure 6 demon-
strate that the WT mice displayed increased muscle (Figure 6A),
liver (Figure 6B) and adipose tissue (Figure 6C) insulin sensitivity
after Rosiglitazone treatment. The AKOmicewere already insulin
sensitive prior to drug treatment (Figure 3) and Rosiglitazone had
no further effects in muscle and fat, but did induce even greater
insulin sensitivity in liver (Figure 6). This suggests that the AKO
mice are relatively resistant to exogenous PPARg stimulation,
most likely because adipocyte PPARg target genes are already
derepressed by the NCoR deletion. Unwanted side effects of
TZD treatment include hemodilution and increased heart weight.
Interestingly, neither were observed in the AKO mice, while, as
expected, the effects of Rosiglitazone treatment to cause hemo-
dilution were the same in both genotypes (Figure S4).
To further explore themechanismsof this relative refractoriness
to TZD treatment, we examined PPARg expression and its phos-
phorylation state inadipose tissue.Choi etal. have recentlyshown
that CDK5-mediated phosphorylation of PPARg at serine 273 is
an important regulatory event (Choi et al., 2010). In turn, PPARg
agonist treatment leads to dephosphorylation of PPARg serineCell 147, 815–273 and dephosphorylation at this site confers
an active transcriptional program, consistent
with an insulin sensitive state. In our current
studies, we found that PPARgmRNA (Figure 4B)
and protein expression were increased in the
AKO mice in adipose tissue extracts (Figure 6D)
or in primary adipocytes (Figure 6E). Importantly,
a substantial decrease in serine 273 phospho-
PPARg was also observed in both adipose
tissue and primary adipocytes, and the ratio of
phospho-PPARg to total PPARg protein was
markedly reduced in the HFD-fed AKO mice
compared toWT. It is unlikely that this decreased
PPARg phosphorylation was due to decreased
CDK5 activity, since CDK5 protein levels and,
more importantly, phospho-CDK5 levels, were
comparablebetweenWTandAKOmice (Figures
6D and 6F). Furthermore, phosphorylation of Rb,another cellular substrate of CDK5, was intact in the AKO cells
(Figure 6G). Rosiglitazone treatment (Figure 6F) led to decreased
PPARg serine 273 phosphorylation in WT animals, as previously
reported by Choi et al. (Choi et al., 2010). Since nonphosphory-
lated PPARg has insulin sensitizing actions, the finding that
NCoR depletion inhibits this phosphorylation event is important
and could contribute to the AKO phenotype. To further explore
the mechanisms for this effect, we treated WT and AKO primary
adipocytes with TNFa. TNFa is known to activate CDK5, and
Figure 6H shows that TNFa treatment led to an increase in serine
273PPARgphosphorylation inWTadipocytes. Importantly, TNFa
did not increase serine 273 PPARg phosphorylation in AKO cells,
demonstrating a cell autonomous effect of NCoR to facilitate
CDK5-mediated PPARg phosphorylation.
The molecular events underlying PPARg phosphorylation
were assessed with a series of coimmunoprecipitation and
mammlian two-hybrid assays. In these studies, we used a
luciferase reporter assay driven by Gal4-PPARg coupled with
VP16-NCoR constructs, encompassing NCoR residues 1–740
(NCoR-N), 742–1798 (NCoR-M), and 1803–2439 (NCoR-C).
The data clearly show a direct interaction between PPARg and
NCoR, and the NCoR interaction site is located in the RID-con-
taining C terminus. Rosiglitazone treatment strongly inhibits
this interaction almost to base line values (Figure 6I). We also
performed coimmunoprecipitation experiments and confirmed826, November 11, 2011 ª2011 Elsevier Inc. 819
Figure 5. Decreased Adipose Tissue
Inflammation in AKO Mice
(A) FACS analysis of F4/80+/CD11b+ cells in
SVCs.
(B) Relative mRNA levels of the macrophage
marker F4/80 in Epi-WAT.
(C) F4/80 immuno staining in epi-WAT.
(D) FACS analysis of F4/80+/CD11b+/CD11c+
cells in SVCs.
(E) Relative mRNA levels of the proinflammatory
M1-like macrophage marker CD11c in Epi-WAT.
(F) Relative mRNA levels of inflammatory and
anti-inflammatory cytokines in Epi-WAT.
(G) Effect of conditioned medium (CM) from WT
and AKO primary adipocytes on macrophage
chemotaxis.
(H) In vivo PKH26 flourescently labeled macro-
phage tracking in WT and AKO mice on HFD.
(I) Subpopulations of recruited PKH26+ macro-
phages.
Values are expressed as mean ± SEM, n = 6 in (A),
(B), (D), and (E), n = 8 in (F), n = 5–6 in (G)–(I),
*p < 0.05, **p < 0.01 for AKO versus WT. See also
Table S1 and Figure S4.earlier reports (Yu et al., 2005), that PPARg coprecipitates with
NCoR in WT cells (data not shown). More importantly, we also
found that PPARg readily precipitates with CDK5 in WT cells
with 55% less PPARg coprecipitated in the AKO cells (Fig-
ure 6J). Rosiglitazone causes dissociation of the PPARg,NCoR
complex (Figure 6I) and this leads to decreased CDK5/PPARg
coprecipitation in WT cells (Figure 6J). Transient transfection
assays showed that full-length NCoR and the NCoR C terminus
enhance TNFa-stimulated CDK5 phosphorylation of PPARg
serine 273 in HEK293T cells (Figure 6K). In the two-hybrid system
(Figure 6L) we used Gal4-CDK5 and VP16-PPARg to show direct
association between PPARg and CDK5. Expression of NCoR
increases this interaction, while Rosiglitazone treatment (which
causes NCoR dismissal) decreases this interaction (Figure 6M).
In the two-hybrid system, we also found no evidence for a direct
interaction between NCoR and CDK5 (data not shown). Taken
together, these results indicate that NCoR directly interacts
with PPARg and, through an allosteric effect, enhances the
ability of PPARg to associate with CDK5. When CDK5 activity
is stimulated, as with TNFa treatment in vitro or obesity-induced820 Cell 147, 815–826, November 11, 2011 ª2011 Elsevier Inc.adipose tissue inflammation in vivo,
PPARg serine 273 phosphorylation is
induced.
Studies of Gene Expression
Since NCoR can interact with other tran-
scription factors, in addition to PPARg,
we compared gene expression profiles
in epi-WAT from HFD-fed WT and HFD-
fed AKO mice. Fold change was calcu-
lated against the transcript levels of the
WT group. The results revealed that 163
genes were upregulated and 107 genes
were downregulated in the AKO group
compared to WT. The most significantlyenhanced pathway in the upregulated group was the annotated
PPARg signaling pathway. qPCR was used to better quantitate
a group of PPARg response genes (Figures 7A and 7B) in
addition to those already shown in Figure 2H. These results
demonstrate that these genes were uniformly upregulated in
the AKOmice compared toWT, and that Rosiglitazone treatment
led to increased expression of these genes in WT animals but
had no effect to further enhance expression in the AKO mice.
These results fortify the conclusion that adipocyte NCoR dele-
tion leads to an activated PPARg transcriptional state which is
not further enhanced by PPARg ligand (TZD) treatment. Consis-
tent with this, RGS2 is a gene known to be downregulated by
PPARg activation and Figure 7B shows that RGS2 expression
is decreased in the AKO mice and that Rosiglitazone treatment
decreases RGS2 expression in WT but not AKO animals. Addi-
tional KEGG analysis revealed that upregulated genes were
also significantly enriched in functionally annotated pathways
including: fatty-acid metabolism, insulin signaling pathway,
and mitochondria and lipid metabolic process. Downregulated
genes were significantly enriched for functional annotations
Figure 6. Effects of Rosiglitazone Treat-
ment and PPARg Serine273 Phosphorylation
(A) IS-GDR in mice with or without Rosiglitazone
treatment.
(B) Percent suppression of HGP (HGP suppres-
sion).
(C) Percent suppression of free-fatty-acid levels
(FFA suppression).
(D) Phospho-PPARg (Ser273) and phospho-CDK5
(Tyr15) levels in epi-WAT.
(E) Phospho-PPARg levels in primary adipocytes.
(F) Phospho-PPARg and phospho-CDK5 levels in
epi-WAT with or without Rosiglitazone treatment.
(G) Phospho-Rb levels in epi-WAT.
(H) TNFainduced PPARg ser 273 phosphoryla-
tion in primary adipocytes.
(I) Mammalian two-hybrid assays in HEK293T cells
using Gal4-PPARg and VP16-NCoR-N (N-terminal
1–740 aa), VP16-NCoR-M (middle 742–1798 aa) or
VP16-NCoR-C (C-terminal 1803-2439 aa). Also
shown is the effect of Rosiglitazone on the PPARg-
NCoR-C interaction.
(J) Coimmunoprecipitation of CDK5 with PPARg in
epi-WAT.
(K) Effects of NCoR, or the NCoR C-terminal
domain, on TNFa-induced PPARg ser 273 phos-
phorylation.
(L) Mammalian two-hybrid assays using Gal4-
CDK5 and VP16-PPARg.
(M) Effect of NCoR and Rosiglitazone on the
PPARg-CDK5 interaction. Values are expressed
as mean ± SEM, n = 6 in (A)–(C), n = 4–5 in (D)–(H),
and (J) *p < 0.05, **p < 0.01 for AKO versus WT.
See also Figure S5.such as natural killer cell-mediated toxicity and immune system
process. The genes associated with the enriched functional
pathways mentioned above are shown in Table S2.
To probe the mechanisms of ligand-independent gene upregu-
lation in AKO cells, we conducted ChIP assays for the PEPCKCell 147, 815–826, Npromoter. As seen in Figure 7C, Rosiglita-
zone treatment led to the expected
increase in coactivator (SRC3) recruitment
to the promoter in WT cells, whereas in
AKO cells, SRC3 occupancy was already
high in the absence of ligand, with no
further increase due to Rosiglitazone.
This pattern corresponds quite closely
to the gene expression results shown in
Figure 7A (first box). In contrast, Gpd1 is
a PPARg-induced gene that was not
constitutively upregulated in the AKO cells
and ChIP assays showed the classical
pattern of Rosiglitazone- mediated SRC3
recruitment in both WT and AKO cells.
DISCUSSION
Adipose tissue serves as an integrator of
various physiological pathways and is atthe key cross roads for regulation of energy balance and glucose
homeostasis (Cusi, 2010; Goossens, 2008; Halberg et al., 2008;
Kahn and Flier, 2000; Qatanani and Lazar, 2007). Nuclear recep-
tors are a family of transcription factors which modulate many
aspects of biologic function, including glucose and energyovember 11, 2011 ª2011 Elsevier Inc. 821
Figure 7. mRNA Levels of PPARg Target Genes in Epi-WAT
(A) mRNA levels of upregulated genes in epi-WAT.
(B) mRNA level of a downregulated gene (RGS2) in epi-WAT.
(C) SRC3 occupancy on PPARg responsive elements (PPRE) in the Pepck/Gpd1 promoters.
Values are expressed as mean ± SEM, n = 6–8 in (A) and (B), *p < 0.05 for AKO versus WT. See also Table S1 and Table S2.homeostasis (Evans et al., 2004; Francis et al., 2003; Tontonoz
and Spiegelman, 2008). NCoR is a major corepressor of nuclear
receptor function (Glass and Rosenfeld, 2000) and, therefore,
should be a regulator of energy and glucose balance. In the
current studies, we have generated adipocyte-specific NCoR
knockout mice and have conducted detailed in vivo and
in vitro studies of adipocyte biology, obesity, inflammation, and
insulin resistance. We find that deletion of NCoR from adipo-
cytes leads to a phenotype which phenocopies constitutive
PPARg activation. The AKO animals become more obese on
HFD than WT mice, due to increased adipocyte hyperplasia.
Despite the increased adiposity, the AKO mice demonstrate
decreased ATM content, reduced tissue inflammation, cell822 Cell 147, 815–826, November 11, 2011 ª2011 Elsevier Inc.autonomous adipocyte insulin sensitivity and enhanced
systemic insulin sensitivity. Interestingly, they are also relatively
refractory to Rosiglitazone treatment. Although NCoR can serve
as a corepressor for multiple nuclear receptors, it is quite striking
that the major phenotype in AKO mice can be traced to unre-
strained PPARg activity. This allows us to infer that in adipo-
cytes, the dominant function of NCoR is to repress PPARg.
Furthermore, since genetic deletion of NCoR in adipocytes is
the initiating event in our model, these studies demonstrate
that unleashing PPARg only in adipose tissue is sufficient to
produce the systemic effects seen with in vivo TZD treatment,
indicating the importance of adipose tissue for the metabolic
effects of these drugs.
The AKO mice exhibited enhanced systemic insulin sensitivity
as demonstrated by improved oral glucose tolerance with a
reduction in hyperinsulinemia, and a greater hypoglycemic
response to insulin during the insulin tolerance test. This
increased insulin sensitivity was quantitated using the hyperinsu-
linemic/euglycemic clamp, as well as ex vivo tissue analyses.
Importantly, the improved insulin sensitivity was not simply
confined to adipose tissue, since increased hepatic and skeletal
muscle insulin sensitivity was clearly demonstrated in the
glucose clamp studies, with a 95% increase in IS-GDR (skeletal
muscle insulin sensitivity) and 136% increase in hepatic insulin
sensitivity (HGP suppression). These in vivo findings were
strongly supported by the tissue measures of insulin signaling
which showed improved insulin-stimulated Akt phosphorylation
in all three insulin target tissues in the AKO animals.
Our studies also explored the physiologic mechanisms under-
lying the amelioration of insulin resistance due to adipocyte
NCoR deletion. For example, it is well known that adipocytes
secrete adipokines which can have systemic endocrine effects
to modulate the tone of insulin action. We found that circulating
levels of HMW adiponectin were increased, whereas, resistin
levels were decreased in the AKO mice, and this combination
could certainly improve insulin resistance. The AKO adipocytes
also displayed increased insulin-stimulated glucose transport
compared to WT primary adipocytes. Furthermore, the effect
of macrophage CM to cause insulin resistance in adipocytes
was partially abrogated in the AKO cells similar to a TZD-treated
state. This demonstrates increased cell autonomous adipocyte
insulin sensitivity, providing an additional mechanism for
improved in vivo insulin resistance.
It has been widely reported that chronic tissue inflammation
can be a major cause of insulin resistance and that macro-
phage-mediated proinflammatory effects are an underlying
mechanism (Donath and Shoelson, 2011; Hotamisligil and Erbay,
2008;Olefsky andGlass, 2010). Herewe show that in HFD/obese
mice, ATM accumulation was reduced in the AKO group and
this was accompanied by decreased expression of proinflamma-
tory genes in the adipose tissue. Interestingly, one of the impor-
tant chemokines released by adipocytes is MCP-1, and PPARg
activation is known to inhibit adipocyte MCP-1 expression and
secretion.We found decreased levels ofMCP-1 in adipose tissue
from the AKOmice, consistent with the activated PPARg pheno-
typeand this couldprovideanexplanation for thedecreasedATM
numbers and reduced levels of inflammation. Indeed, we provide
direct evidence consistent with this idea by showing that CM
harvested from AKO compared to WT primary adipocytes has
a much lower capacity to stimulate macrophage chemotaxis.
In vivo macrophage tracking studies were also consistent with
this concept. Here we found that when fluorescently labeled
monocytes were injected into recipient HFD WT or AKO mice,
a substantial decrease in macrophage appearance in adipose
tissue was observed in the AKO animals. Taken together, these
data suggest the overall idea that adipocyte NCoR deletion leads
to decreased chemokine secretion from adipocytes, causing
reduced ATM content and decreased inflammation, contributing
to the enhanced state of insulin sensitivity.
It is of interest that the ultimate phenotype of the recruited
ATMs is substantially different in the WT versus AKO mice. InWT mice, > 90% of the fluorescently labeled recruited ATMs
assume the M1-like, CD11c+ proinflammatory phenotype,
whereas, only 50% of the recruited ATMs in the AKO mice
become CD11c+. This means that in the AKO mice there is
a 6-fold increase in the proportion of these recruited ATMswhich
become M2-like, CD11c- ATMs. Thus, not only are the chemo-
tactic signals reduced in AKO adipose tissue causing decreased
total ATM migration, but differences in tissue cues also promote
a higher degree of polarization to the M2-like ATM phenotype.
We were also able to study the WT and AKO mice after Rosi-
glitazone treatment and found that the predicted effects of this
drug to improve insulin sensitivity were readily demonstrated in
the HFD/obese WT mice. On the other hand, the HFD AKO
mice were refractory to the effects of TZD treatment in adipose
tissue and muscle. This is consistent with the PCR and gene
array results which showed that the PPARg transcriptional
program is fully activated in the AKO adipose tissue and that
Rosiglitazone treatment has very little additional effect. On the
other hand, a clear improvement in hepatic insulin action was
observed in the Rosiglitazone-treated AKOmice. Since the tran-
scriptional effects of Rosiglitazone action involve dismissal of
NCoR from PPARg target genes, this mechanism cannot be
operative in adipocytes from the AKO mice. However, since
NCoR expression was not altered in liver, the Rosiglitazone-
mediated improvement in hepatic insulin sensitivity could still
occur. With this in mind, it is interesting to note that, while Rosi-
glitazone treatment led to enhanced hepatic insulin action in the
AKO mice, pretreatment hepatic insulin sensitivity was already
greater in the AKO animals compared to WT. This indicates
that in vivo TZD-induced hepatic insulin sensitization includes
both direct drug effects in the liver and indirect effects, most
likely originating in adipose tissue.
TZD treatment causes fluid retention as manifested by hemo-
dilution, edema, and often times increased heart weight. As
measured by hematocrit and heart weight, the AKO mice do
not show signs of hemodilution (Figures S4C and S4D), demon-
strating that the site of action of TZDs to cause edema is outside
of the adipocyte, most likely in the kidney, where NCoR and the
PPARg system are fully preserved in our mice. Rosiglitazone
causes the expected effect on hemodilution in both genotypes
(Figure S4C), also consistent with a site of action outside of the
adipose tissue. These results suggest that adipocyte-specific
stimulation of the PPARg program could be an effective means
to avoid some of the unwanted side effects associated with clas-
sical TZD treatment.
An important finding in these studies involves the status of
PPARg phosphorylation at serine 273. Choi et al. have demon-
strated that CDK5 can phosphorylate PPARg at position 273
(Choi et al., 2010), whereas, PPARg agonists lead to decreased
phosphorylation at this site. They have also shown that the de-
phosphorylated form of PPARg is transcriptionally active,
inducing a gene signature profile conducive to insulin sensitiza-
tion. This finding prompted us to examine the status of PPARg
serine 273 phosphorylation in our studies. We found that serine
273 phosphorylation was decreased in whole adipose tissue
and in isolated adipocytes from the AKO mice compared to
WT. This difference was not due to reduced CDK5 activity, since
the amount of phospho-CDK5 in adipose tissue and theCell 147, 815–826, November 11, 2011 ª2011 Elsevier Inc. 823
phosphorylation state of another CDK5 substrate, Rb, was
comparable between the two groups. From these findings, we
infer that NCoR is necessary for CDK5-mediated PPARg serine
273 phosphorylation. This may also help explain why PPARg
agonists cause decreased PPARg serine 273 phosphorylation,
since PPARg agonists dismiss NCoR from the PPARg transcrip-
tional complex. This decrease in PPARg serine 273 phosphory-
lation is likely an important factor in the insulin sensitive pheno-
type in these mice.
Given the potential importance of this finding to decreased
insulin resistance, we conducted experiments to elucidate the
mechanisms for the reduced PPARg phosphorylation in the
absence of NCoR. TNFa is an activator of CDK5, and Choi
et al. have demonstrated that TNFa treatment of adipocytes
increases serine 273 PPARg phosphorylation. In the current
studies, we found that TNFa treatment ofWT primary adipocytes
led to increased serine 273 PPARg phosphorylation, whereas,
TNFa had no such effect in AKO cells. This demonstrates that
the ability of adipocyte NCoR deletion to decrease serine 273
PPARg phosphorylation is a cell autonomous effect. Further-
more, we show that PPARg coprecipitates with CDK5, demon-
strating the presence of these two proteins in a molecular
complex. Importantly, coprecipitation of PPARg with CDK5
was markedly decreased in the AKO cells. Both two-hybrid
and Co-IP studies show a direct interaction between NCoR
and PPARg, and this interaction is inhibited by Rosiglitazone
treatment. We also show that NCoR enhances TNFa-stimulated
CDK5-mediated PPARg serine 273 phosphorylation, while Rosi-
glitazone treatment, which dissociates NCoR from the complex,
inhibits this phosphorylation event. In the two-hybrid system, the
data show a direct interaction between PPARg and CDK5, and
NCoR has a substantial effect to enhance this association while
Rosiglitazone treatment attenuates it. In contrast to the strong
inteactions between PPARg and NCoR, and PPARg and
CDK5, we found only a negligible direct interaction between
NCoR and CDK5. We also observed that TNFa treatment does
not increase CDK5/PPARg association, consistent with the
view that the TNFa effect is conferred by augmenting the enzy-
matic activity of CDK5, rather than its association with its PPARg
target protein. In sum, when NCoR is decreased by genetic dele-
tion or Rosiglitazone treatment, the CDK5/PPARg interaction is
attenuated and subsequent phosphorylation of PPARg serine
273 is reduced. When NCoR expression is enhanced, the inter-
action between CDK5 and PPARg is augmented, as is PPARg
serine 273 phosphorylation. All of these results are consistent
with the concept that the NCoR interaction with PPARg pro-
duces an allosteric effect to enhance the ability of PPARg to
associate with CDK5.
With respect to the constitutively upregulated genes, a tran-
scriptionalmechanismwould predict lowbasal coactivator occu-
pancy of the promoter in WT cells with an increase upon
Rosiglitazone treatment. Due to NCoR deletion in AKO cells,
coactivator occupancy should be high in the absence of ligand
with no further increase due to Rosiglitazone. This is precisely
the pattern observed in our ChIP studies for SRC3 on the PEPCK
promoter (Figure 7C). In contrast, Gpd1 is a PPARg gene which
was not upregulated in the AKO cells and ChIP assays showed
the classical pattern of Rosiglitazone-induced coactivator824 Cell 147, 815–826, November 11, 2011 ª2011 Elsevier Inc.recruitment inbothWTandAKOcells. Thedegreeof insulin sensi-
tivity in adipose tissue and muscle was the same in untreated
AKOmice as in Rosiglitazone treatedWT animals, and, therefore,
it seems logical to suggest that the set of constitutively upregu-
lated genes in the AKO mice, contains the key genes essential
for TZD-mediated improvement of insulin sensitivity.
In these studies, we have shown that adipocyte-specific dele-
tion of the corepressor NCoR, specifically activates the PPARg
transcriptional program and promotes the nonphosphorylated
PPARg serine 273 state in these cells. This leads to increased
adipogenesis, reduced adipose tissue ATM content and inflam-
mation, improved cell autonomous adipocyte insulin sensitivity,
changes in adipokine secretion, and increased systemic insulin
sensitivity, all of which phenocopy the TZD treated in vivo state.
Thus, while NCoR can corepress multiple nuclear receptors,
these data demonstrate selective cell type effects of this core-
pressor, indicating that it’s dominant action in adipocytes is to
corepress PPARg. These results raise the possibility that NCoR
mayprove to be a useful target for future therapeutics in the treat-
ment of Type 2 diabetes and other insulin resistant diseases.
EXPERIMENTAL PROCEDURES
Creation of Control and Adipocyte-Specific NCoR Knockout Mice
Mice carrying floxed alleles of NCoR were provided by Dr. Johan Auwerx.
These mice were backcrossed to the C57BL/6J strain for nine generations.
Mice were bred with transgenic mice harboring Cre recombinase driven by
aP2 promoter (He et al., 2003) to create the following genotypes: NCoRfl/fl
(control), NCoRfl/fl-ap2Cre (AKO).
ITTs, GTTs, and Hyperinsulinemic Euglycemic Clamp Study
Glucose and insulin tolerance tests were performed on 6 hr fasted mice. For
GTTs, animals were IP injected with dextrose (1 g/kg, Hospira, Inc), whereas
for ITTs 0.5 units/kg of insulin (Novolin R, Novo-Nordisk) was IP injected. Blood
was drawn at 0, 15, 30, 60, and 120 min after dextrose or 0, 15, 30, 60, and
90 min after insulin injection. Mouse clamps were performed as previously
described (He et al., 2003; Li et al., 2010; Lu et al., 2010). Briefly, dual catheters
(MRE-025, Braintree Scientific) were implanted in the right jugular vein and
tunneled subcutaneously and exteriorized at the back of the neck. The mice
were allowed to recover for 3 to 4 days before the clamp procedure. After
6 hr fasting, the clamp experiments began with a constant infusion (5 mCi/hr)
of D-[3-3H] glucose (Du Pont-NEN, Boston, MA). After 90 min of tracer
equilibration and basal sampling at t = –10 and 0 min, glucose (50% dextrose,
variable infusion; Abbott) and tracer (5 mCi/hr) plus insulin (6 mU/kg/min) were
infused into the jugular vein. Blood from the tail vein was drawn at 10 min inter-
vals and analyzed for glucose to maintain the integrity of the glucose clamp.
Blood was taken at t = –10, 0 (basal), 110, and 120 (end of experiment) min
to determine glucose-specific activity, insulin, and free fatty acids (FFA).
Steady-state conditions (120 mg/dl ± 5 mg/dl) were confirmed at the end of
the clamp by ensuring that glucose infusion and plasma glucose levels were
maintained constant for a minimum of 30 min. HGP and GDR were calculated
in the basal state and during the steady-state portion of the clamp. Tracer-
determined rates were quantified by using the Steele equation (Steele,
1959). At steady state, the rate of glucose disappearance, or total GDR, is
equal to the sum of the rate of endogenous glucose productions (HGP) plus
the exogenous (cold) GIR. The IS-GDR is equal to the total GDR minus the
basal glucose turnover rate.
Adipocyte Isolation, SVCs Isolation, and FACS Analysis
Adipocyte, SVCs isolation, and FACS analysis were performed as previously
described (Li et al., 2010).Briefly, epididymal fatpadswereweighed, rinsed three
times in PBS, and then minced in FACS buffer (PBS + 1% low endotoxin BSA).
Tissue suspensions were treated with collagenase (1 mg/ml, Sigma-Aldrich) for
30 min, and then were filtered through a 100 mm filter (BD Biosciences).
After centrifugation at 500 g for 5 min, the supernatant containing adipocytes
was removed and the pallet containing SVCs fraction was incubated with RBC
lysis buffer (eBioscience) for 5 min followed by another centrifugation (300 g,
5 min) and resuspension in FACS buffer. SVCs were incubated with Fc Block
(BD Biosciences) for 20 min at 4C before staining with fluorescently labeled
primary antibodies or control IgGs for 30min at 4C. F4/80-APC FACS antibody
was purchased from AbD Serotec (Raleigh, NC); FITC-CD11b and PE-CD11c
FACS antibodies were from BD Biosciences. Cells were gently washed twice
and resuspended in FACS buffer with propidium iodide (Sigma). SVCs were
analyzed using a FACSAria flow cytometer (BD Biosciences). Unstained, single
stains and Fluorescence Minus One controls were used for setting compensa-
tion and gates. The events were first gated based on forward-area versus side
scatter-areaaswell as side scatter-height versus side scatter-width and forward
scatter-height versus forward scatter-width for a total of three dual parameter
plots to gate out aggregates and debris. Single color controls were used to
calculate compensation using the FACSDiva software. A plot of forward scatter
versus propidium iodide was used as the fourth gate to identify individual, live
cells. To measure markers with the maximum sensitivity, each fluorochrome
was plotted versus propidium iodide, and polygons were drawn, angled with
the aid of the Fluorescence Minus One controls.
Confocal Microscopy of Mouse Adipose Tissue
The method for immunofluorescene study of mouse adipose tissue was
carried out as previously described (Lumeng et al., 2008). Briefly, mice were
euthanized and slowly perfused with 10 ml of 1% paraformaldehyde in PBS
via intracardiac injection. 1 cm3 fat-pad samples were excised and blocked
for 1 hr in 5% BSA in PBS with gentle rocking at RT. For detection of intracel-
lular antigens, samples were blocked in 5%BSA in PBS and subsequently per-
meabilized in 0.3% Triton X-100. Fat samples were incubated with primary
antibodies in blocking buffer (0.5–1 mg/ml) for overnight at 4C. After three
washes, samples were incubated with fluorochrome-conjugated secondary
antibodies for 1 hr at RT. Fat pads were imaged on an inverted confocal micro-
scope (Olympus Fluoview 1000). Anti-F4/80 and caveolin1 were purchased
from Abcam and BD Biosciences, respectively.
In Vivo Tracking Assay
Monocyte Preparation
Leukocyte pools fromC57BL/6 male mice 12 weeks of age, bled from the retro
orbital sinus, were subjected to red blood cell lysis and monocyte subsets
were enriched with EasySep mouse monocyte enrichment kit (STEMCELL
tech, Vancouver, BC) followed the manufacturer’s instructions.
In Vitro Labeling
Isolated monocytes (5 3 106 to 10 3 106) were washed once in serum-free
medium (RPMI-1640) and suspended in 2 ml of Diluent solution C (included
in the PKH26 labeling kit). Two ml of PKH26 (Sigma Chemical Co. St Louis,
MO) at 23 103 M in Diluent C was added and mixed, and the cells were incu-
bated for 10 min at room temperature in the dark. The staining reaction was
halted by addition of an equal volume (2 ml) of medium supplemented with
10% FBS. The mixture was centrifuged and the cells were washed once and
resuspended in serum-containing medium.
In Vivo Migration
Subsequent to labeling with PKH26 monocytes were counted and 1 3 106
viable cells were suspended in 0.2 ml PBS and injected into the femoral vein
of the recipient mice. Two days after injection, the ATMswere immediately iso-
lated from visceral fat tissue and analyzed by FACS.
Other Methods
See Supplemental Information.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
two tables, and five figures and can be found with this article online at
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